Medcap Q3 2026: Margin Beat, Fair Value Trimmed - Redeye

Medcap Q3 2026: Margin Beat, Fair Value Trimmed - Redeye

Redeye updates its estimates and valuation following MedCap’s Q3 2026 report. Sales were in line with our estimate, while adjusted EBITA beat by c16% on a 20.9% margin. We nudge down our fair value to SEK600 (SEK620), mainly on a higher WACC.

Länk till analysen i sin helhet: https://www.redeye.se/research/1189176/medcap-q3-2026-margin-beat-fair-value-trimmed?utm_source=finwire&utm_medium=RSS